替罗非班联合丁苯酞治疗急性进展性脑梗死的临床效果观察
2021-03-25李月
李月




【摘要】 目的:觀察替罗非班联合丁苯酞治疗急性进展性脑梗死的临床效果分析。方法:选取2019年10月-2020年10月本院收治的154例急性进展性脑梗死患者,按照随机数字表法将患者分为对照组和试验组,每组77例。对照组采用常规治疗,试验组在对照组的基础上加用替罗非班和丁苯酞。比较两组疗效及治疗前后血液生化指标(血小板聚集率、全血高切黏度、全血低切黏度、同型半胱氨酸)、神经功能缺损评分及Barthel指数。结果:治疗前,两组血小板聚集率、全血高切黏度、全血低切黏度、Hcy比较,差异均无统计学意义(P>0.05);治疗后,两组血小板聚集率、全血高切黏度、全血低切黏度、Hcy均低于治疗前,且试验组均低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组NIHSS评分及Barthel指数比较,差异均无统计学意义(P>0.05);治疗后,两组NIHSS评分均低于治疗前,Barthel指数均高于治疗前,且试验组NIHSS评分低于对照组,Barthel指数高于对照组,差异均有统计学意义(P<0.05)。试验组总有效率为97.40%高于对照组的87.01%,差异有统计学意义(P<0.05)。结论:替罗非班联合丁苯酞治疗急性进展性脑梗死,可降低血小板聚集率与血黏度水平,并降低机体内的Hcy水平,改善患者神经功能缺损水平,改善患者生活能力,提升临床疗效。
【关键词】 替罗非班 丁苯酞 急性进展性脑梗死
Clinical Effect of Tirofiban Combined with Butylphthalide in the Treatment of Acute Progressive Cerebral Infarction/LI Yue. //Medical Innovation of China, 2021, 18(28): 0-068
[Abstract] Objective: To observe the clinical effect of Tirofiban combined with Butylphthalide in the treatment of acute progressive cerebral infarction. Method: A total of 154 patients with acute progressive cerebral infarction admitted to our hospital from October 2019 to October 2020 were selected, and they were divided into control group and experimental group according to random number table method, 77 cases in each group. The control group received conventional treatment, and the experimental group received Tirofiban combined with Butylphthalide on the basis of the control group. The efficacy was compared between two groups, blood biochemical indexes (platelet aggregation rate, whole blood high-cut viscosity, whole blood low-cut viscosity, homocysteine), neurological deficit score and Barthel index before and after treatment were compared between two groups. Result: Before treatment, there were no significant differences in platelet aggregation rate, whole blood high-cut viscosity, whole blood low-cut viscosity and Hcy between two groups (P>0.05); after treatment, the platelet aggregation rate, whole blood high-cut viscosity, whole blood low-cut viscosity and Hcy of both groups were lower than those before treatment, those of the experimental group were lower than those of the control group, the differences were statistically significant (P<0.05). Before treatment, there were no significant differences in NIHSS scores and Barthel index between two groups (P>0.05); after treatment, NIHSS scores of both groups were lower than those before treatment, Barthel indexes of both groups were higher than those before treatment, NIHSS score of the experimental group was lower than that of the control group, Barthel index of the experimental group was higher than that of the control group, the differences were statistically significant (P<0.05). The total effective rate of experimental group was 97.40%, which was higher than 87.01% of control group, the difference was statistically significant (P<0.05). Conclusion: Tirofiban combined with Butylphthalide in the treatment of acute progressive cerebral infarction can reduce the platelet aggregation rate and blood viscosity level, reduce the level of Hcy in the body, improve the level of neurological impairment, improve the living ability of patients, and improve the clinical efficacy.
[Key words] Tirofiban Butylphthalide Acute progressive cerebral infarction
First-author’s address: Huludao Central Hospital, Huludao 125000, China
doi:10.3969/j.issn.1674-4985.2021.28.016
脑梗死是老年常见病,随着我国人口老龄化程度加剧,患病人数也逐渐增多[1]。急性进展性脑梗死是在缺血性脑梗死发生后的48~72 h之内,突然出现的一种神经功能呈阶梯性加重的脑梗死[2-3]。……
